Soligenix, Inc. (SNGX)

Market Cap	7.58M
Revenue (ttm)	960,615
Net Income (ttm)	-8.07M
Shares Out	10.38M
EPS (ttm)	-2.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,029,085
Open	0.760
Previous Close	0.980
Day's Range	0.711 - 0.890
52-Week Range	0.380 - 10.350
Beta	1.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2023

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of infl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX

Financial Performance

In 2022, Soligenix's revenue was $948,911, an increase of 15.12% compared to the previous year's $824,268. Losses were -$13.80 million, 9.94% more than in 2021.